This year, scientists at the pharmaceutical company Gilead announced that a new injectable drug seems to provide exceptional protection from HIV for six months. In one clinical trial involving South African and Ugandan girls and young women, the shot, called lenacapavir, reduced HIV infections by 100 percent in the intervention group. This breakthrough represents a significant advance in preventive treatment, especially in regions heavily affected by the virus and lacking access to ongoing medicinal support.
My top breakthrough was Casgevy, a gene-editing therapy for patients with sickle-cell anemia, building on decades of research on CRISPR, an immune defense system. This therapy has shown promising results in improving the lives of patients suffering from this genetic disorder, marking a new chapter in the application of gene-editing technology. It symbolizes how continuous research and development lead to substantive advances in treating complex diseases that affect many lives.
Collection
[
|
...
]